semaglutide and sibo SIBO-C Dysbiosis and nutrition in steatotic

Schifano, F

You deserve a partner who understands the science of body transformation

Semaglutide Weekly Injection Active Ingredient in Ozempic and Wegovy 15% Body Weight Reduction GLP-1 Receptor Agonist FDA Approved for Type 2 Diabetes (2017) and Weight Loss (2021) Most Common Side Effects: Nausea, Diarrhea, Vomiting, Constipation, Indigestion, and Abdominal Pain Tirzepatide Weekly Injection Active Ingredient in Mounjaro 20% Body Weight reduction Dual GLP-1 and GIP Receptor Agonist FDA Approved for Type 2 Diabetes (2022) and on Fast-track for Weight Loss Approval in 2023 Most Common Side Effects: Nausea, Diarrhea, Vomiting, Constipation, Indigestion, and Abdominal Pain These injections are GLP-1 medications that have been FDA-approved for Type 2 diabetes because of their ability to lower blood sugar and raise insulin levels

Both compounds require reconstitution equipment : bacteriostatic water, appropriate syringes (typically insulin syringes for cagrilintide and larger syringes for retatrutide high-dose protocols), alcohol swabs, and proper storage containers

Comparison of direct boiling method with commercial kits for extracting fecal microbiome Dna by Illumina sequencing of 16S rrna tags